Neuravi said today it launched its EmboTrap minimally invasive thrombectomy device for the treatment of acute ischemic stroke in Europe.
The Embotrap device functions by capturing clots and allowing blood flow to resume immediately after the clot has been secured in patients who have experienced a stroke, CEO Eamon Brady told MassDevice.com in an interview in June.
“One of the things Neuravi has done that’s unique to all of our competition is we have launched a huge research effort over the last 5 years in understanding the properties of clots – the cause of ischemic stroke – and we’re going to continue to invest in that program,” Brady said.
The device is designed with a dual-layer stent-like structure as well as an integrated distal protection zone designed to reduce the risk of fragments of the clot dislodging during retrieval, the company said.
“The device has some features that no other technology has. It’s the only device that traps the clot inside the device structure, and at the same time has a tiny micro-stent that creates a blood flow channel across the device and that allows the healing process to start immediately after deployment,” Brady said. “It has an in-built, 3-dimensional fragment-catching zone at its far, most distal end to capture any particles that might break up during the procedure. The device traps the clot and is removed from the patient and nothing is left behind.”
The EmboTrap won CE Mark approval in the European Union in late 2014. The device is being sold and distributed in Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Spain, Sweden and Switzerland, Neuravi said.
“The EmboTrap device represents a new wave in innovation for stent retrievers based on clot research and a fuller understanding of the underlying challenge. We are excited to announce our launch and pleased that, following the compelling clinical data published earlier this year, use of thrombectomy devices for endovascular stroke therapy is on the rise, which should save and improve the lives of many patients,” Brady said in a press release.
Neuravi is pursuing FDA clearance for the device, and has an investigational device exemption study, the Arise II trial, slated to begin enrolling patients this year.
In June, Neuravi said it raised $21 million in a Series B round for its Embotrap minimally invasive thrombectomy device.
The Series B round was led by European equity firm Life Science Partners and joined by existing backers Fountain Healthcare Partners, Delta Partners and the Western Development Commission, Galway-based Neuravi said.
